Related Experiment Video
Updated: Jun 24, 2025
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.0K
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Jeffrey A Klomp1,2, Jennifer E Klomp1, Clint A Stalnecker1,2
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Science (New York, N.Y.)
|June 6, 2024
Summary
The KRAS oncogene drives cancer growth, but its mechanisms are unclear. Our study reveals ERK signaling is key to KRAS-mutant cancer growth and resistance to targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The KRAS oncogene is a key driver of various cancers, but the precise molecular mechanisms underlying its oncogenic activity and associated therapeutic resistance remain incompletely understood.
- Understanding KRAS-driven gene transcription is crucial for developing effective cancer treatments.
Purpose of the Study:
- To establish a systemwide transcriptional portrait of KRAS and extracellular signal-regulated kinase (ERK) dependency in KRAS-mutant cancers.
- To delineate the molecular mechanisms driving cancer growth and inhibitor resistance.
- To identify key pathways regulated by ERK signaling in KRAS-mutant cancers.
Main Methods:
- Systemwide gene transcription profiling in KRAS-mutant cancer models.
- Integration of transcriptomic data with proteomic analysis (phosphoproteome and total proteome).
- Analysis of ERK mitogen-activated protein kinase (MAPK) cascade activity.
Main Results:
- A novel KRAS-dependent gene signature was identified, distinct from previously reported signatures.
- KRAS-driven transcription is predominantly mediated by the ERK MAPK cascade.
- ERK deregulation of the anaphase promoting complex/cyclosome (APC/C) and cell cycle machinery was highlighted as critical for pancreatic ductal adenocarcinoma (PDAC) growth.
Conclusions:
- ERK signaling plays a critical mechanistic role in driving KRAS-mutant tumor growth.
- ERK signaling is implicated in resistance to KRAS-ERK MAPK targeted therapies.
- This study provides new insights into KRAS-driven oncogenesis and potential therapeutic strategies.
Related Concept Videos
02:38The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:07MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:33Cancer-Critical Genes I: Proto-oncogenes
8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
01:24Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K